Russian version English version
About the Journal
Editorial Board
Instructions for Authors
Information for Readers and Authors
Current Issue
Archive
Contact Us
Search

Send manuscript
 


Volume 21   Issue 1   Year 2026
References

  1. World Health Organization. Dengue and severe dengue. WHO Fact Sheets. 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue.
  2. Waggoner J.J., Gresh L., Vargas M.J., Ballesteros G., Tellez Y., Soda K.J., Sahoo M.K., Nuñez A., Balmaseda A., Harris E., et al. Viremia and clinical presentation in Nicaraguan patients infected with Zika virus, chikungunya virus, and dengue virus. Clin. Infect. Dis. 2016;63:1584–1590. doi: 10.1093/cid/ciw589
  3. Dehghani R., Kassiri H. A review on epidemiology of dengue viral infection as an emerging disease. Res. J. Pharm. Technol. 2021;14:2296–2301. doi: 10.52711/0974-360X.2021.00406
  4. Leowattana W., Leowattana T. Dengue hemorrhagic fever and the liver. World J. Hepatol. 2021;13:1968–1976. doi: 10.4254/wjh.v13.i12.1968
  5. Sinha S., Singh K., Ravi Kumar Y.S., Roy R., Phadnis S., Meena V., Bhattacharyya S., Verma B. Dengue virus pathogenesis and host molecular machineries. J. Biomed. Sci. 2024;31. Article No. 43. doi: 10.1186/s12929-024-01030-9
  6. Ng W.C., Soto-Acosta R., Bradrick S.S., Garcia-Blanco M.A., Ooi E.E. The 5′ and 3′ untranslated regions of the flaviviral genome. Viruses. 2017;9. Article No. 137. doi: 10.3390/v9060137
  7. Gautam S., Thakur A., Rajput A., Kumar M. Anti-dengue: A machine learning-assisted prediction of small molecule antivirals against dengue virus and implications in drug repurposing. Viruses. 2023;16. Article No. 45. doi: 10.3390/v16010045
  8. Swarbrick C.M.D., Basavannacharya C., Chan K.W.K., Chan S.-A., Singh D., Wei N., Phoo W.W., Luo D., Lescar J., Vasudevan S.G. NS3 helicase from dengue virus specifically recognizes viral RNA sequence to ensure optimal replication. Nucleic Acids Res. 2017;45:12904–12920. doi: 10.1093/nar/gkx1127
  9. Xu T., Sampath A., Chao A., Wen D., Nanao M., Chene P., Vasudevan S.G., Lescar J. Structure of the dengue virus helicase/nucleoside triphosphatase catalytic domain at a resolution of 2.4 Å. J. Virol. 2005;79:10278–10288. doi: 10.1128/JVI.79.16.10278-10288.2005
  10. Luo D., Wei N., Doan D.N., Paradkar P.N., Chong Y., Davidson A.D., Kotaka M., Lescar J., Vasudevan S.G. Flexibility between the protease and helicase domains of the dengue virus NS3 protein conferred by the linker region and its functional implications. J. Biol. Chem. 2010;285:18817–18827. doi: 10.1074/jbc.M109.090936
  11. Benarroch D., Selisko B., Locatelli G.A., Maga G., Romette J.-L., Canard B. The RNA helicase, nucleotide 5′-triphosphatase, and RNA 5′-triphosphatase activities of dengue virus protein NS3 are Mg²⁺-dependent and require a functional Walker B motif in the helicase catalytic core. Virology. 2004;328:208–218. doi: 10.1016/j.virol.2004.07.004
  12. Silva E.M., Conde J.N., Allonso D., Ventura G.T., Coelho D.R., Carneiro F.A., Mohana-Borges R., Bozza P.T., Silva J.L., Mohana-Borges R., et al. Dengue virus nonstructural 3 protein interacts directly with human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and reduces its glycolytic activity. Sci. Rep. 2019;9:2651. doi: 10.1038/s41598-019-39157-7
  13. Kok B.H., Lim H.T., Lim C.P., Lai N.S., Leow C.Y., Leow C.H. Dengue virus infection—a review of pathogenesis, vaccines, diagnosis and therapy. Virus Res. 2023;324. Article No. 199018. doi: 10.1016/j.virusres.2022.199018
  14. Chauhan N., Gaur K.K., Asuru T.R., Guchhait P. Dengue virus: pathogenesis and potential for small molecule inhibitors. Biosci. Rep. 2024;44. Article No. BSR20240134. doi: 10.1042/BSR20240134
  15. Rahman M.M., Biswas S., Islam K.J., Paul A.S., Mahato S.K., Ali M.A., Halim M.A. Antiviral phytochemicals as potent inhibitors against NS3 protease of dengue virus. Comput. Biol. Med. 2021;134. Article No. 104492. doi: 10.1016/j.compbiomed.2021.104492
  16. Behl T., Rocchetti G., Chadha S., Zengin G., Bungau S., Kumar A., Mehta V., Uddin M.S., Khullar G., Setia D. et al. Phytochemicals from plant foods as potential source of antiviral agents: an overview. Pharmaceuticals (Basel). 2021;14. Article No. 381. doi: 10.3390/ph14040381
  17. Khan R.A., Hossain R., Siyadatpanah A., Al-Khafaji K., Khalipha A.B.R., Dey D., Asha U.H., Biswas P., Saikat A.S.M., Islam M.T. Diterpenes/diterpenoids and their derivatives as potential bioactive leads against dengue virus: a computational and network pharmacology study. Molecules. 2021;26. Article No. 6821. doi: 10.3390/molecules26226821
  18. Lim S.Y.M., Chieng J.Y., Pan Y. Recent insights on anti-dengue virus (DENV) medicinal plants: review on in vitro, in vivo and in silico discoveries. All Life. 2021;14:1–33. doi: 10.1080/26895293.2020.1856192
  19. Agrawal P.K., Agrawal C., Blunden G. Naringenin as a possible candidate against SARS-CoV-2 infection and in the pathogenesis of COVID-19. Nat. Prod. Commun. 2021;16:1–7. doi: 10.1177/1934578X211066723
  20. Zandi K., Teoh B.T., Sam S.S., Wong P.F., Mustafa M.R., AbuBakar S. In vitro antiviral activity of fisetin, rutin and naringenin against dengue virus type-2. J. Med. Plants Res. 2011;5:5534–5539. doi: 10.5897/JMPR11.1046
  21. Frabasile S., Koishi A.C., Kuczera D., Silveira G.F., Verri W.A. Jr., Duarte dos Santos C.N., Bordignon J. The citrus flavanone naringenin impairs dengue virus replication in human cells. Sci. Rep. 2017;7. Article No. 41864. doi: 10.1038/srep41864
  22. Nahmias Y., Goldwasser J., Casali M., van Poll D., Wakita T., Chung R.T., Yarmush M.L. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology. 2008;47:1437–1445. doi: 10.1002/hep.22197
  23. Lyu S.-Y., Rhim J.-Y., Park W.-B. Antiherpetic activities of flavonoids against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in vitro. Arch. Pharm. Res. 2005;28:1293–1301. doi: 10.1007/BF02978215
  24. da Silva C.C.F., Salatino A., da Motta L.B., Negri G., Salatino M.L.F. Chemical characterization, antioxidant and anti-HIV activities of a Brazilian propolis from Ceará State. Braz. J. Pharmacogn. 2019;29:309–318. doi: 10.1016/j.bjp.2019.04.001
  25. Mirza S.B., Salmas R.E., Fatmi M.Q., Durdagi S. Virtual screening of eighteen million compounds against dengue virus: combined molecular docking and molecular dynamics simulations study. J. Mol. Graph. Model. 2016;66:99–107. doi: 10.1016/j.jmgm.2016.03.008
  26. Saqallah F.G., Abbas M.A., Wahab H.A. Recent advances in natural products as potential inhibitors of dengue virus with a special emphasis on NS2B/NS3 protease. Phytochemistry. 2022;202. Article No. 113362. doi: 10.1016/j.phytochem.2022.113362
  27. Satpathy R., Acharya S., Behera R. Computational design, docking, and molecular dynamics simulation study of RNA helicase inhibitors of dengue virus. J. Vector Borne Dis. 2024;61:536–546. doi: 10.4103/JVBD.jvbd_188_23
  28. Lee M.F., Tan S.L., Ahemad N., Hamid A.A.A., Hishamuddin S.A.S.N., Batumalaie K., Afzal S., Wu Y.S. Molecular docking and dynamics simulation reveal withanolides as potent antivirals against dengue virus. S. Afr. J. Bot. 2024;169:426–434. doi: 10.1016/j.sajb.2024.04.045
  29. Alagarasu K., Patil P., Kaushik M., Chowdhury D., Joshi R.K., Hegde H.V., Kakade M.B., Hoti S.L., Cherian S., Parashar D. In vitro antiviral activity of potential medicinal plant extracts against dengue and chikungunya viruses. Front. Cell Infect. Microbiol. 2022;12. Article No. 866452. doi: 10.3389/fcimb.2022.866452
  30. Joseph B., Sankarganesh P., Ichiyama K., Yamamoto N. In vitro study on cytotoxic effect and anti-DENV-2 activity of Carica papaya L. leaf. Front. Life Sci. 2015;8:18–22. doi: 10.1080/21553769.2014.924080
  31. Kaushik S., Kaushik S., Kumar R., Dar L., Yadav J.P. In vitro and in silico activity of Cyamopsis tetragonoloba (Gaur) L. supercritical extract against the dengue virus serotype 2. VirusDisease. 2020;31:470–478. doi: 10.1007/s13337-020-00624-9
  32. Duda-Madej A., Stecko J., Sobieraj J., Szymańska N., Kozłowska J. Naringenin and its derivatives—health-promoting phytobiotic against resistant bacteria and fungi in humans. Antibiotics (Basel). 2022;11. Article No. 1628. doi: 10.3390/antibiotics11111628
  33. Kabier M., Gambacorta N., Trisciuzzi D., Kumar S., Nicolotti O., Mathew B. MzDOCK: A free ready-to-use GUI-based pipeline for molecular docking simulations. J. Comput. Chem. 2024;45:1980–1986. doi: 10.1002/jcc.27390
  34. Koes D.R., Baumgartner M.P., Camacho C.J. Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise. J. Chem. Inf. Model. 2013;53:1893–1904. doi: 10.1021/ci300604z
  35. Patel C.N., Kumar S.P., Pandya H.A., Rawal R.M. Identification of potential inhibitors of coronavirus hemagglutinin-esterase using molecular docking, molecular dynamics simulation and binding free energy calculation. Mol. Divers. 2021;25:421–433. doi: 10.1007/s11030-020-10135-w
  36. Odhar H.A., Hashim A.F., Ahjel S.W., Humadi S.S. Molecular docking and dynamics simulation analysis of the human FXIIa with compounds from the Mcule database. Bioinformation. 2023;19:160–166. doi: 10.6026/97320630019160
  37. Land H., Humble M.S. YASARA: A tool to obtain structural guidance in biocatalytic investigations. Methods Mol. Biol. 2018;1685:43–67. doi: 10.1007/978-1-4939-7366-8_4
  38. Krieger E., Vriend G. New ways to boost molecular dynamics simulations. J. Comput. Chem. 2015;36:996–1007. doi: 10.1002/jcc.23899
  39. Acharya S., Satpathy R. Molecular docking and dynamics assessment of naringenin targeting NS3–NS4B interaction in dengue virus (DENV-2). Discover Chemistry. 2025;2. Article No. 311. doi: 10.1007/s44371-025-00409-3
  40. Satpathy R., Padhan P., Behera R., Ratha J. Investigating the endocrine disruption potential of sclareol through docking and molecular dynamics simulation methods. Mathematical Biology and Bioinformatics. 2025;20:122–134. doi: 10.17537/2025.20.122
  41. Patil R., Das S., Stanley A., Yadav L., Sudhakar A., Varma A.K. Optimized hydrophobic interactions and hydrogen bonding at the target–ligand interface lead the pathways of drug designing. PLoS One. 2010;5. Article No. e12029. doi: 10.1371/journal.pone.0012029
  42. Pantsar T., Poso A. Binding affinity via docking: fact and fiction. Molecules. 2018;23. Article No. 1899. doi: 10.3390/molecules23081899
  43. Amir M., Mohammad T., Kumar V., Alajmi M.F., Rehman M.T., Hussain A., Alam P., Dohare R., Hassan M.I. Structural analysis and conformational dynamics of STN1 gene mutations involved in coat plus syndrome. Front. Mol. Biosci. 2019;6. Article No. 41. doi: 10.3389/fmolb.2019.00041
  44. Weiss M.S., Brandl M., Sühnel J., Pal D., Hilgenfeld R. More hydrogen bonds for the (structural) biologist. Trends Biochem. Sci. 2001;26:521–523. doi: 10.1016/S0968-0004(01)01935-1
  45. Fatriansyah J.F., Boanerges A.G., Kurnianto S.R., Pradana A.F., Fadilah S.S.N., Surip S.N. Molecular dynamics simulation of ligands from Anredera cordifolia (Binahong) against the main protease (Mpro) of SARS-CoV-2. J. Trop. Med. 2022;2022. Article No. 1178228. doi: 10.1155/2022/1178228
  46. Eissa I., Al-Karmalawy A., Dahab M.A., Metwaly A.M., Elhady S.S., Elkaeed E.B., Darwish K.M. Molecular docking and dynamics simulation revealed the potential inhibitory activity of ACEIs against SARS-CoV-2 targeting hACE2 receptor. Front. Chem. 2021;9. Article No. 627639. doi: 10.3389/fchem.2021.627639
  47. Sharma K., Singh M., Sharma S.C. Revolutionizing antiviral therapeutics: in silico approaches for emerging and neglected RNA viruses. Curr. Pharm. Des. 2024;30:3276–3290. doi: 10.2174/0113816128322226240815063730
  48. Dass K., Prakash N., Manogar P., Murugesan R. Current insights and future perspectives of in silico molecular docking in dengue virus proteins inhibition: a review. Aspects Mol. Med. 2024;4. Article No. 100050. doi: 10.1016/j.amolm.2024.100050
  49. Roy D., Manumol M., Alagarasu K., Parashar D., Cherian S. Phytochemicals of different medicinal herbs as potential inhibitors against dengue serotype 2 virus: a computational approach. Mol. Biotechnol. 2024;66:1–14. doi: 10.1007/s12033-024-01282-8
  50. Fatriansyah J.F., Rizqillah R.K., Yandi M.Y. Molecular docking and molecular dynamics simulation of fisetin, galangin, hesperetin, hesperidin, myricetin, and naringenin against polymerase of dengue virus. J. Trop. Med. 2022;2022. Article No. 7254990. doi: 10.1155/2022/7254990
  51. Arafah A., Rehman M.U., Mir T.M., Wali A.F., Ali R., Qamar W., Khan R., Ahmad A., Aga S.S., Alqahtani S. et al. Multi-therapeutic potential of naringenin (4′,5,7-trihydroxyflavonone): Experimental evidence and mechanisms. Plants. 2020;9. Article No. 1784. doi: 10.3390/plants9121784
  52. Yang J., Zhou Y., Ban Y., Mi J., He Y., Li X., Wang K., Zhu G., Liu W., Tan Z., et al. Development of naringenin-O-alkylamine derivatives as multifunctional agents for the treatment of Alzheimer’s disease. J. Enzyme Inhib. Med. Chem. 2022;37:792–816. doi: 10.1080/14756366.2022.2041627
  53. Lather A., Sharma S., Khatkar A. Naringenin derivatives as glucosamine-6-phosphate synthase inhibitors: synthesis, antioxidants, antimicrobial, preservative efficacy, molecular docking and in silico ADMET analysis. BMC Chem. 2020;14. Article No. 41. doi: 10.1186/s13065-020-00693-3
  54. Souza R.O.D., Hilgenberg L.C., Pinto A.C., Costa R.A., Simplicio F.G., Lima E.S. Novel flavanone naringenin derivative with anti-inflammatory activity. J. Braz. Chem. Soc. 2024;35. Article No. e-20230157. doi: 10.21577/0103-5053.20230157
  55. Mohammed N.H., Mostafa M.I., Al-Taher A.Y. Augmentation effects of novel naringenin analogues and ciprofloxacin as inhibitors for Nora efflux pump (EPIs) and pyruvate kinase (PK) against MRSA. J. Anim. Vet. Adv. 2015;14:386–392.
  56. Chakraborty P., Acharya K., Sarkar J., Habtemariam S., Sharifi-Rad J., Cho W.C. Antiviral activities of naringenin and its derivatives as adjuvant treatment against SARS-CoV-2 infections. In: Anti-SARS-CoV-2 Activity of Flavonoids. Boca Raton: CRC Press. P. 218–222. doi: 10.1201/9781003433200-18
  57. Frabasile S., Koishi A.C., Kuczera D., Silveira G.F., Verri W.A. Jr., Duarte dos Santos C.N., Bordignon J. The citrus flavanone naringenin impairs dengue virus replication in human cells. Sci. Rep. 2017;7. Article No. 41864. doi: 10.1038/srep41864
  58. Rajasekar M. Adverse effect of synthesized naringenin derivatives investigated with zebrafish (Danio rerio) embryos. Results Chem. 2020;2. Article No. 100039. doi: 10.1016/j.rechem.2020.100039
  59. Ávila E.P., Mendes L.A., De Almeida W.B., Dos Santos H.F., De Almeida M.V. Conformational analysis and reactivity of naringenin. J. Mol. Struct. 2021;1245. Article No. 131027. doi: 10.1016/j.molstruc.2021.131027
  60. Kasat Y.K., Potale Y., Kumar A., Jamwal V. Exploring the pharmacological potential of naringenin and its nanopArticle No.s: A review on bioavailability and solubility enhancement strategies. In: BIO Web Conf. 2024;86. Article No. 01030. doi: 10.1051/bioconf/20248601030
Table of Contents
Original Article
Acharya S., Satpathy R. Computational Evaluation of the Phytochemical Naringenin and Its Derivatives against Dengue Virus DENV2. Ìàthematical biology and bioinformatics. 2026;21(1):121-138. doi: 10.17537/2026.21.121
(published in English)

Abstract (eng.)
Abstract (rus.)
Full text (eng., pdf)
References

 
  Copyright IMPB RAS © 2005-2026